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A challenge in investigating the effect of public health policies on cigarette consumption and exposure
arises from variation in a smoker’s exposure from cigarette to cigarette and the considerable differences
between smokers. In addition, limited data are available on the effects of spontaneous product switching
on a smoker’s cigarette consumption and exposure to smoke constituents. Over 1000 adult smokers of
the same commercial 10 mg International Organization for Standardization (ISO) tar yield cigarette were
recruited into the non-residential, longitudinal study across 10 cities in Germany. Cigarette consumption,
mouth level exposure to tar and nicotine and biomarkers of exposure to nicotine and 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone were measured every 6 months over a 3 and a half year period. Cigarette
consumption remained stable through the study period and did not vary signiﬁcantly when smokers
spontaneously switched products. Mouth level exposure decreased for smokers (n = 111) who switched
to cigarettes of 7 mg ISO tar yield or lower. In addition, downward trends in mouth level exposure esti-
mates were observed for smokers who did not switch cigarettes. Data from this study illustrate some of
the challenges in measuring smokers’ long-term exposure to smoke constituents in their everyday
environment.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The long-term health risks associated with cigarette smoke
exposure have been extensively studied and are well established
(US Department of Health and Human Services, 1982, 1983,
1984). Epidemiologic studies have shown that the risk of develop-
ing smoking-related diseases is dose related and increases with
duration of smoking and consumption and that cessation generally
leads to reductions in the risks of developing disease (US
Department of Health and Human Services, 2004; International
Agency for Research on Cancer, 2004).Despite the beneﬁts of smoking cessation, there are smokers
who cannot or are unwilling to stop smoking completely and this
has promoted alternative tobacco harm reduction strategies such
as mandating lowering of toxicants per unit of nicotine in cigarette
smoke (Burns et al., 2008) and the development of potentially
reduced-exposure products (Stratton and Wallace, 2001).
In 2007 the World Health Organization (WHO) Study Group on
Tobacco Product Regulation (TobReg) issued a technical report on
the scientiﬁc basis of tobacco product regulation, which included
a list of research needs in relation to ‘‘The contents and design fea-
tures of tobacco products: their relationship to dependence poten-
tial and consumer appeal’’ (WHO, 2007). Included in this list are:
the need to assess whether an increase or decrease in nicotine con-
tent per unit (e.g., cigarette) would be beneﬁcial to public health;
method development to assess the effects of contents and designs
on toxicity, consumer appeal and the potential for dependency;
investigation of the potential effect on tobacco-use patterns of
efforts to control contents, appeal and dependence potential
through population surveillance studies and monitoring of unin-
tended consequences of those policies.
A challenge in investigating the effect of such public health poli-
cies on cigarette consumption and exposure arises from the fact
that a smoker’s exposure is known to vary from cigarette to
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between smokers is considerably greater (Hammond et al., 2005).
An additional consideration is the possibility for compensatory
smoking behaviour to occur in response to smoking a cigarette of
higher or lower tar and nicotine yield (Benowitz, 2001).
Compensation is possible through changes in puff volume, fre-
quency or consumption. There have been a number of published
studies that have reported the extent of compensation using cross-
sectional studies of smokers of cigarettes across a range of
machine-derived yields (Byrd et al., 1998; Hecht et al., 2005;
Mendes et al., 2009) or through interventional product switching
studies (Benowitz et al., 2005, 2009; Mendes et al., 2008;
Shepperdet al., 2011). A reviewof the literature concluded that com-
pensation was on average incomplete (partial) when switching to
lower yield cigarettes (Scherer, 1999; Scherer and Lee, 2014) and
was generally achieved through changes in smoking intensity rather
than an increase in the number of cigarettes smoked. Very few stud-
ies have measured compensatory smoking behaviour in smokers
who spontaneously switched products (Lynch and Benowitz,
1987; Muhammad-Kah et al., 2011) and at multiple timepoints.
This paper reports data from a longitudinal study of over 1000
German smokers of a commercial 10 mg ISO (International
Organization for Standardization) tar product in their everyday
environment over a period of 3 and a half years. The primary objec-
tive of the study was to assess patterns of cigarette consumption
and exposure to cigarette smoke using biomarkers of tobacco
smoke exposure and mouth level exposure (MLE) estimates of tar
and nicotine. In addition, we studied the effects of spontaneous
product switching on cigarette consumption and exposure to cigar-
ette smoke. Secondary objectives were to assess the extent of any
compensatory smoking behaviour when smokers switched to
lower tar and nicotine yield cigarettes.
In studying the long-term behaviours of smokers of the same
product and measuring a number of endpoints we aimed to
develop a suitable methodology for monitoring the smoking habits
of smokers in their everyday environment over an extended period
of time. This aimed to address some of the research needs raised by
TobReg (WHO, 2007) whilst providing additional information on
the effects of spontaneous product switching on smokers’ cigarette
consumption and exposure to smoke constituents.2. Materials and methods
2.1. Study design
Over 1000 smokers who smoked a minimum of 8 cigarettes a
day of the same commercial 10 mg ISO tar yield product, Lucky
Strike Red (LSR), for at least 6 months were recruited into the
study; a non-residential, observational, multicentre, longitudinal
study across 10 cities in Germany.
The study design included unrestricted periods and three clini-
cal visits over a 12-day ﬁeldwork period, every 6 months (referred
to as a timepoint). On day one (visit 1) of the ﬁeldwork period, sub-
jects were requested to smoke their own purchased cigarettes for
days 2–8 and to collect cigarette remains in aluminium containers
provided. On day 9 (visit 2) subjects returned to the clinic with the
aluminium containers and the contents counted to provide a mea-
sure of average daily consumption (ADC). Subjects were provided
with a day’s worth of their own cigarette product, a ﬁlter
cutter/collector device to store part-ﬁlters from smoked cigarettes
(Ashley et al., 2011) and containers for 24 h urine collection.
Subjects were requested to smoke only the provided cigarettes
during day 11 and to collect all urine from the second void to
and including the ﬁrst void of day 12. At the ﬁnal visit (day 12),
subjects returned the 24 h urine sample, the ﬁlter cutter/collectordevice containing part-ﬁlters and provided a saliva sample under
the supervision of a study nurse.
Clinical aspects of the study were conducted by an independent
contract research organisation in compliance with the principles
documented in the Declaration of Helsinki (World Medical
Association, 1996) and the International Conference on
Harmonisation Guidelines for Good Clinical Practice (International
Conference on Harmonisation, 1996). The study is registered with
Current Controlled Trials (ID: ISRCTN95019245). The study proto-
col and informed consent form were approved by the Ethics
Committee of Bayerischen Landesärztekammer. Subjects were
required to provide written informed consent and were provided
with details of local smoking advice centres. Full details of the study
design, subject screening, and study visit activities and measure-
ments are described by Cunningham et al. (2014).
2.2. Products
Subjects were provided with one day’s supply of cigarettes of
their current product, at each timepoint of the study, with each
product sourced from a single manufacturing batch. Subjects were
provided with cigarettes for use during the period of 24 h urine and
spent ﬁlter collection to minimise variation between subjects’
products and to allow sample analysis to be conducted on the same
batch of cigarettes as those smoked by the study subjects. ISO tar
and nicotine yields of each product supplied were determined
according to ISO standards (International Organization for
Standardization, 2000).
2.3. Exposure measures
Estimated mouth level exposures to tar and nicotine were
obtained by analysis of spent part-ﬁlters (St. Charles et al., 2009).
Daily estimates of mouth level exposure were calculated using
the per cigarette estimates multiplied by the number of cigarettes
smoked on day 11 of the ﬁeldwork period. Each subject’s average
daily cigarette consumption was calculated from the total number
of cigarette remains collected from days 2–8 of the ﬁeldwork per-
iod. Twenty-four hour urine samples were measured for nicotine
equivalents (NEQ, the molar sum of nicotine, cotinine, trans-30-hy-
droxycotinine (OH-cotinine), nicotine-N-glucuronide, cotinine-N-
glucuronide and trans-30-hydroxycotinine-O-glucuronide) (Meger
et al., 2002); total NNAL (urinary 4-(methylnitrosamino)-1-(3-pyr-
idyl)-1-butanol (NNAL) and NNAL-glucuronides) (Scherer et al.,
2007) and creatinine (Blaszkewicz and Liesenhoff-Henze, 2012).
Saliva samples were analysed for cotinine and OH-cotinine accord-
ing to published methodology (Scherer et al., 2007).
2.4. Data sampling and statistical analysis
Statistical analysis was conducted using SAS version 9.3 (SAS
Institute, Cary, NC, USA). Data were analysed separately for each
endpoint, using a linear mixed model for repeated measures analy-
sis of variance (ANOVA) with SAS PROC MIXED, to assess group
changes over time for all MLE, biomarkers of exposure and con-
sumption measurements using least squares (LS) means and 95%
conﬁdence intervals. Smoker groups for each timepoint were
deﬁned based on categorisation of each subject according to the
ISO tar yield of their current product as follows: LSR (10 mg ISO
tar), 8–10 mg (8–10 mg ISO tar) and 67 mg (67 mg ISO tar). The
ANOVA model included the ﬁxed term effects of smoker group
(LSR, 8–10 mg or 67 mg), timepoint, gender, age category at enrol-
ment (21–29, 30–39, 40–49, 50–64) and smoker group by time-
point interaction. The ﬁxed term main effects and interaction
term were removed from the model if not statistically signiﬁcant
(p > 0.05). As a multi-centre study, the linear mixed model
Table 1
Subject demographic and baseline characteristics.
Baseline timepoint
Number of subjects 1011
Gender, n (%)
Males 652 (64)
Females 359 (36)
Age, years, n (%)
21–29 418 (41)
30–39 353 (35)
40–49 173 (17)
50–64 67 (7)
Mean (SD) 33 (9)
Consumption, mean (SD)
Self-reported 15.8 (6.0)
Average daily consumptiona 13.3 (6.2)
Day 11b 15.7 (6.6)
Exposure data, mean (SD)
MLE tar (mg/cig) 17.83 (5.79)
MLE nicotine (mg/cig) 1.50 (0.49)
MLE tar (mg/day) 282.6 (154.4)
MLE nicotine (mg/day) 23.98 (13.27)
Urinary NEQ (mg/day) 13.91 (8.95)
Urinary total NNAL (ng/day) 307.72 (226.50)
Salivary cotinine (ng/mL) 266.03 (164.84)
Salivary OH-cotinine (ng/mL) 90.70 (73.60)
n = number, SD-standard deviation, MLE = mouth-level exposure, NEQ = nicotine
equivalents, NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, OH-cotini-
ne = trans-30-hydroxycotinine.
a Consumption based on all cigarettes smoked over 7 days.
b Consumption based on the number of spent ﬁlter-tips collected during the 24 h
collection period from the cigarettes provided.
Table 2
Smoker group and brand variant composition by timepoint.
Timepoint
1a 2 3 4 5 6
Total subjects (n) 820 744 662 611 582 546
LSR group (n) 741 614 527 469 436 395
8–10 mg groupb (n) 39 58 62 71 72 77
67 mg groupc (n) 40 72 73 71 74 74
Total brand variants (n) 30 44 39 46 50 43
Brand variants 8–10 mg group (n) 19 27 24 26 27 22
Brand variants 6 7 mg group (n) 10 16 14 19 22 20
a TP1 = timepoint 1, the ﬁrst timepoint to assess spontaneous product switching.
b 8–10 mg group are those subjects who smoked a product of 8–10 mg ISO tar
(not including the LSR product).
c 67 mg group are those smokers who smoked a product of 67 mg ISO tar.
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model when not statistically signiﬁcant (p > 0.05). The ﬁrst time-
point (TP0) was used as baseline to account for possible subject dif-
ferences at the start of the study. When the main effects of
timepoint or age category were found to be signiﬁcant, cumulative
contrast comparisons were made with adjustment for multiple
comparisons. When the interaction term was found to be signiﬁ-
cant, contrasts were made between smoker groups within each
timepoint, with adjustment for multiple comparisons. Descriptive
statistics were calculated for demographic characteristics and
baseline consumption and exposure data.
Compensation index was deﬁned as the proportional change in
a subject’s exposure measurement relative to the proportional
change in ISO determined yield. A compensation index per subject
was calculated when switching from LSR to a product of ISO tar
yield of 7 mg or lower at adjacent timepoints and then for subse-
quent timepoints where the subjects remains smoking a product
of ISO tar yield of 7 mg or lower, according to the equation:
CiX ¼ 1 logðexposure2Þ  logðexposure1Þ
logðyield2Þ  logðyield1Þ
 
where CiX is the extent of compensation and exposure1 and yield1
are the levels of the exposure endpoint and ISO yield prior to the
switch, respectively, and exposure2 and yield2 the levels following
the switch (Frost et al., 1995). A CiX value of zero represents no
compensation, whilst a value of 1 represents complete com-
pensation. Compensation indices were calculated for subsequent
timepoints where a subject remained smoking a product of 7 mg
ISO tar or lower, to assess the effect of switch duration. This
approach created switching events ranging from 6 to 36 months
duration. Compensation indices were analysed using a linear mixed
model to assess the effect of switch duration.
3. Results
3.1. Subjects and baseline characteristics
A total of 1191 subjects gave their written consent to partici-
pate in the study, of which 1088 passed inclusion criteria and were
enrolled in the study. A total of 1019 subjects completed the base-
line assessment (TP0), of which 1011 were included in the baseline
dataset, ﬁve subjects being excluded for protocol non-compliance
and a further three because of errors in sample collection. A total
of 546 subjects completed the ﬁnal timepoint (TP6). Subjects’
demographic characteristics, and baseline daily cigarette con-
sumption and exposure data are shown in Table 1.
3.2. Product switching
Table 2 summarises the number of subjects in each smoker
group per timepoint and the total number of brand variants
smoked.
3.3. Repeated measures analysis
Table 3 summarises the signiﬁcant effects in the linear mixed
model for repeated-measures analysis of mouth level exposure,
biomarkers of exposure and consumption.
3.3.1. Mouth level exposure and cigarette consumption
On average values for MLE to tar and nicotine per cigarette were
lower for the 67 mg group compared with the LSR and 8–10 mg
groups. Values for the 67 mg group were lower than the LSR and
8–10 mg groups at each timepoint, though downward trends for
the LSR and 8–10 mg groups over time reduced the magnitude ofthe differences. For MLE to tar estimates, statistical differences
were found between the 67 mg and LSR groups at timepoints 1–
3 and between 67 mg and 8–10 mg groups at timepoints 1 and
2, with a maximum difference of 3.04 mg tar/cigarette (16%)
(Fig. 1a). For MLE to nicotine estimates, statistical differences were
found between the 67 mg and LSR smokers at timepoints 1 and 3,
with a maximum difference of 0.20 mg nicotine/cigarette (12%)
(Fig. 1b).
Average daily cigarette consumption and day 11 cigarette con-
sumption did not show signiﬁcant differences between smoker
groups or across the timepoints of the study. Both average daily
cigarette consumption and day 11 consumption for the age group
21–29 was statistically lower than that observed for all other age
groups.
MLE to tar and nicotine per day was lower at each timepoint for
the 67 mg group compared with the LSR group, with differences of
54.1 mg tar/day (18%) and 3.57 mg nicotine/day (15%) observed at
timepoint 3 (Fig. 1c and 1d). Mean values for the 67 mg group
Table 3
Fitted estimates and statistical signiﬁcance from linear mixed model for repeated measures analysis per endpoint.
Endpoint
MLE tar
(mg/cig)
MLE nicotine
(mg/cig)
MLE tar
(mg/day)
MLE nicotine
(mg/day)
ADC Day 11
consumptionc
Urinary NEQ
(mg/day)
Urinary total
NNAL (ng/day)
Salivary cotinine
(ng/mL)
Salivary OH-
cotinine (ng/mL)
Smoker Groupa ⁄⁄⁄ ⁄⁄ ⁄ N.S. N.S. N.S. ⁄ ⁄⁄⁄ ⁄⁄⁄ ⁄⁄
LSR 18.57 1.50 290.5 23.49 – – 12.74 378.24 290.12 94.76
8–10 mg 18.46 1.51 284.9 23.33 – – 13.68 414.24 300.67 99.01
67 mg 16.93 1.41 262.8 21.70 – – 11.33 332.39 256.66 82.78
Gender N.S. N.S. ⁄⁄ ⁄ ⁄ N.S. N.S. ⁄ N.S. N.S.
Female – – 270.0 22.22 13.3 – – 363.06 – –
Male – – 288.9 23.46 13.8 – – 386.86 – –
Timepoint ⁄⁄⁄ ⁄⁄⁄ ⁄⁄⁄ ⁄ N.S. N.S. ⁄⁄⁄ ⁄⁄⁄ ⁄⁄⁄ ⁄⁄⁄
1 18.95 1.51 287.6 23.00 – – 11.45 339.39 266.97 81.85
2 18.46 1.51 289.5 23.61 – – 12.66 304.84 276.69 93.89
3 18.08 1.44 284.6 22.65 – – 14.06 305.82 278.14 93.18
4 18.48 1.48 285.8 22.87 – – 13.28 440.45 325.21 106.88
5 17.12 1.39 269.2 21.81 – – 11.13 432.17 268.4 82.14
6 16.84 1.50 259.8 23.12 – – 12.92 427.09 279.5 95.16
Age category N.S. N.S. ⁄⁄ ⁄⁄ ⁄ ⁄⁄ N.S. ⁄⁄⁄ ⁄⁄ ⁄⁄
21–29 – – 258.6 21.28 13.0 14.5 – 323.23 286.47 86.80
30–39 – – 275.6 22.69 13.6 15.5 – 366.25 290.94 89.27
40–49 – – 284.3 23.07 13.4 15.3 – 386.58 265.06 87.14
50–64 – – 299.2 24.33 14.2 16.1 – 423.78 287.47 105.53
TP⁄SGb ⁄⁄⁄ ⁄⁄⁄ ⁄ ⁄ N.S. N.S. N.S. ⁄⁄ N.S. N.S.
MLE = mouth level exposure, ADC = average daily consumption, based on all cigarettes smoked over 7 days, NEQ = nicotine equivalents, NNAL = 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol, OH-cotinine = trans-30-hydroxycotinine, N.S. = not signiﬁcant (p > 0.05), ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001.
a Smoker group: 8–10 mg group are those subjects who smoked a product of 8–10 mg ISO tar (not including the LSR product); 67 mg group are those smokers who smoked
a product of 67 mg ISO tar.
b TP * SG = Timepoint smoker group interaction. Timepoint and smoker group main effects were not removed from the model when the interaction of these parameters was
signiﬁcant, even if individually they were not statistically signiﬁcant.
c Consumption based on the number of spent ﬁlter-tips collected during the 24 h collection period from the cigarettes provided.
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exception of timepoint 1 for MLE to nicotine per day. Daily expo-
sure was lowest in the age group 21–29 compared to all other
groups, and lower for the age groups 21–29 and 30–39 compared
to 40–49 and 50–64.
3.3.2. Nicotine biomarkers of exposure
The mean 24 h urinary NEQ value for the 67 mg group was sta-
tistically signiﬁcantly lower than the 8–10 mg group and close to
statistically signiﬁcantly lower than the LSR group. The mean val-
ues of salivary cotinine and OH-cotinine for the 67 mg group were
statistically signiﬁcantly lower than the LSR and 8–10 mg groups.
Whilst the effect of timepoint was signiﬁcant for NEQ, no obvious
trends were identiﬁed (Fig. 2a). Analysis by timepoint for salivary
cotinine and OH-cotinine showed unusually high values at time-
point 4, with no obvious explanation for the observations
(Fig. 2c and d).
3.3.3. Total NNAL per day
Total NNAL per day showed lower mean values for the 67 mg
group compared with the LSR and 8–10 mg groups. All smoker
groups showed a step change at timepoint 4, although the extent
of the increase was smaller for the 67 mg group compared with
the LSR and 8–10 mg groups (Fig. 3). At timepoint 4, the mean
value for the 67 mg group was signiﬁcantly lower than the LSR
group by 96.2 ng total NNAL/day (21%) and the 8–10 mg group
by 130.2 ng total NNAL/day (26%).
3.4. Compensation index
Calculation of the extent of compensatory smoking behaviour
was assessed by considering changes in exposure endpoints on a
per cigarette and per day basis for MLE estimates to tar and nico-
tine and for 24 h urinary NEQ. Table 4 shows compensation indicescalculated when a smoker switched from LSR to a product of 7 mg
ISO tar or lower at adjacent timepoints. The median compensation
index values were less than one but greater than zero for each
measurement, indicating incomplete (partial) compensation. The
degree of compensation was similar when calculated using the
exposure endpoints of MLE to tar and nicotine per cigarette, 0.81
and 0.84, respectively. The degree of compensation increased mar-
ginally when calculated on a daily basis for MLE to tar and nicotine,
0.85 and 0.89, respectively. Compensation calculated using 24 h
nicotine equivalents yielded a value of 0.78. Table 5 shows com-
pensation indices calculated for those subjects whose remained
smoking a product of 7 mg ISO or lower for one or more
timepoints.
Analysis of compensation indices by switch duration showed a
statistically signiﬁcant effect of switch duration for MLE to tar and
nicotine on a per day basis. Contrast analysis revealed a downward
trend with increasing switch duration, but was not statistically sig-
niﬁcant. There was no effect of switch duration on the com-
pensation indices for MLE measures on a per cigarette basis or
for NEQ.4. Discussion
This study was conducted to evaluate an approach for conduct-
ing long-term assessments of the patterns of cigarette consump-
tion and exposure to cigarette smoke in a large population of
adult smokers using biomarkers of tobacco smoke exposure and
mouth level exposure estimates of tar and nicotine in their every-
day environment. Whilst clinical conﬁnement based studies pro-
vide more accurate, less variable data compared with non-
residential studies, some inﬂuence of participation in the study is
likely, whereas non-residential based studies may provide data
more representative of the smoker’s normal behaviour. As the
objective of the study was to investigate smokers in their own
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Fig. 1. Mouth level exposure to tar/cigarette (1a), nicotine/cigarette (1b), tar/day (1c) and nicotine/day (1d) to reﬂect signiﬁcant interaction of smoker group and timepoint.
Data shown are LS means and 95% conﬁdence intervals.
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biomarkers of exposure as they are tobacco-speciﬁc and therefore
not inﬂuenced by environmental and dietary sources (Hatsukami
et al., 2006; Hecht, 2002). In addition, the use of the part-ﬁlter
methodology has gained popularity recently and represents a
non-invasive technique to provide estimates of MLE to nicotine
and tar, in the subject’s own environment (Clayton et al., 2010;
Ding et al., 2012; Pauly et al., 2009; Polzin et al., 2009).
Mendes et al. (2008) aimed to address these concerns by inclu-
sion of both a randomized, controlled, short-term phase and an
unrestricted long-term follow-up phase in assessing the effects of
forced switching. In that study, fewer subjects consented to con-
tinue in the long-term follow-up and for 2 of the 3 study groups,
50% of the subjects did not complete the study. In this study over
1000 smokers of the same 10 mg ISO tar product were recruited,
a total of 546 subjects completed the ﬁnal timepoint of the study,
of which 462 subjects attended all seven timepoints. The higher
than expected subject retention rate may be attributable to the
non-conﬁnement study design and the possibility for subjects to
miss given timepoints. The provision of one day’s worth of cigar-
ettes per timepoint in this study is unlikely to have inﬂuenced sub-
ject retention rates.
Given that the reliability of self-reported cigarette consumption
measures has been questioned (Mariner et al., 2011; Mendes et al.,
2009) we measured average daily consumption from all cigarettes
smoked across 7 days and the number of cigarettes smoked during
the 24 h urine collection period (day 11). Cigarette consumption as
measured by the two methods showed no signiﬁcant variationover the duration of the study or as a consequence of product
switching. These ﬁndings are consistent with the trends observed
by Guyatt et al. (1989), who studied a group of smokers for
5 months smoking their own cigarette product, followed by a
forced switch to a cigarette with an ISO tar yield of at least 3 mg
lower for 6 months. A longitudinal study of continuing smokers
reported reductions in consumption over a 5 year period, though
evidence of a survey effect was detected (Yong et al., 2012).
However, increases in consumption have been reported in both
clinical conﬁnement (Shepperd et al., 2011) and non-conﬁned
study designs (Mendes et al., 2008; Sarkar et al., 2008). The provi-
sion of free cigarettes may have contributed to the results reported
in those studies. In our study, subjects were provided with just one
day’s worth of cigarettes per timepoint and thus we may have
avoided this issue.
In assessing the subjects’ exposure and consumption data
throughout the study, each subject’s baseline data are considered
in the linear mixed model, hence each subject acts as their own
control. For MLE to tar per cigarette over the duration of the study,
the effect of timepoint was statistically signiﬁcant as was smoker
group. Analysis of the interaction of smoker group and timepoint
on the MLE estimates showed signiﬁcant differences between the
LSR and 67 mg groups at timepoints 1–3. This is presumably a
result of switching to a cigarette of lower ISO tar yield, of at least
3 mg, as this difference was not observed in smokers who side-
switched to products of 8–10 mg ISO tar yield. A maximum differ-
ence of 3.04 mg tar/cig (16% relative to LSR group) was observed.
Furthermore, differences were detected between the 67 mg and
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Fig. 2. 24 h urinary nicotine equivalents (2a), 24 h urinary creatinine (2b), salivary cotinine (2c) and salivary hydroxycotinine (2d) to reﬂect signiﬁcant effect of timepoint.
Data shown are LS means and 95% conﬁdence intervals.
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Fig. 3. 24 h urinary total NNAL to reﬂect signiﬁcant interaction of smoker group
and timepoint. Data shown are LS means and 95% conﬁdence intervals.
Table 4
Compensation indices following a switch from LSR to a product of 67 mg ISO tar at
adjacent timepoints.
Exposure endpoint n Compensation index, median
(interquartile range Q1–Q3)
MLE tar/cigarette 99 0.81 (0.45–1.17)
MLE nicotine/cigarette 99 0.84 (0.39–1.18)
MLE tar/day 99 0.85 (0.31–1.47)
MLE nicotine/day 99 0.89 (0.17–1.53)
NEQ 98 0.78 (1.54–1.92)
MLE = mouth level exposure, NEQ = nicotine equivalents.
A. Cunningham et al. / Regulatory Toxicology and Pharmacology 72 (2015) 8–16 138–10 mg groups at timepoints 1 and 2. However, these trends were
not maintained for subsequent timepoints with reductions
observed for the LSR and 8–10 mg groups at timepoints 5 and 6.
Mouth level exposure to nicotine per cigarette data showed trends
similar to MLE to tar. Signiﬁcant differences were detected
between the LSR and 67 mg groups at timepoints 1 and 3, with a
maximum difference of 0.20 mg nicotine/cig (12% relative to LSR
group). The downward trend observed for the LSR group’s MLE totar was less pronounced for MLE to nicotine and showed an
increase at timepoint 6. The reason for the noticeable variation in
MLE to tar and nicotine per cigarette for the LSR group is unknown
and whilst analytical factors cannot be ruled out, it is unlikely as
sample analysis was randomised across all subjects per timepoint.
Over time, trends in daily MLE to tar and nicotine reﬂected the
general trends observed for the per cigarette estimates. A signiﬁ-
cant difference was detected between the 67 mg and LSR groups
at timepoint 3 of 54.1 mg tar/day (17.5 % relative to LSR group)
and 3.57 mg nicotine/day (14.7% relative to LSR group). The addi-
tional variation introduced from the cigarette consumption data
produced larger conﬁdence intervals and in conjunction with the
downward trend in MLE tar/cig for the LSR group, resulted in no
other signiﬁcant comparisons.
High variability in urinary biomarkers of cigarette smoke expo-
sure has been observed in studies with ambulatory collections
Table 5
Compensation indices for subjects who switched to and remained smoking a product
of ISO tar yield of 7 mg or lower, for one or more timepoints.
Exposure endpoint Compensation Index, median, by switch
duration (months)
6 12 18 24 30 36
MLE tar/cigarette 0.81 0.69 0.79 0.74 0.76 0.74
MLE nicotine/cigarette 0.84 0.69 0.70 0.67 0.63 0.90
MLE tar/day 0.85 0.90 0.72 0.73 0.59 0.52
MLE nicotine/day 0.89 0.92 0.74 0.94 0.54 0.83
NEQ 0.78 0.56 1.06 0.62 1.08 0.89
Maximum observations, n 99 84 66 54 41 24
MLE = mouth level exposure, NEQ = nicotine equivalents.
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varied between timepoints, with no obvious trends. Whilst the
extent of compliance in urine collection will affect variability, the
trend in urinary creatinine (Fig. 2b) suggests that other sources
of variation, such as individual’s metabolism rates for nicotine,
contribute to the overall variation over time. Despite, the observed
variation over time, a signiﬁcant difference of 2.35 mg nicotine/day
was observed in the 24 h urinary NEQ between the 67 mg and 8–
10 mg groups. The difference between the 67 mg and LSR group,
whilst not statistically signiﬁcant, was equivalent to 1.4 mg
nicotine/day.
The use of salivary biomarkers of exposure eliminates the con-
cerns of sample integrity of 24 h ambulatory urine collections but
is susceptible to the inﬂuence of proximity to recently smoked
cigarettes, therefore leading to increased variability between smo-
kers’ levels. The effect of smoker group closely matched that
observed for NEQ, with lower values observed for the 67 mg group
in comparison to the LSR and 8–10 mg groups for both cotinine and
OH-cotinine. The values of cotinine and OH-cotinine were consis-
tent over time, with the exception of distinctly high values at time-
point 4. The reason for the high salivary biomarker values at this
timepoint is not understood and whilst no obvious analytical bias
was identiﬁed, the fact that the increase occurred across all smoker
groups indicates a common cause such as analytical accuracy or
sample storage conditions.
The inclusion of the urinary biomarker NNAL provides a bio-
marker of the particulate phase toxicant 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK), (carcinogenic to humans;
International Agency for Research on Cancer, Group 1). Total
NNAL values were statistically lower for the 67 mg group com-
pared with the LSR and 8–10 mg groups and increased at timepoint
4 across all smoker groups, although the extent of the increase was
greatest for the LSR and 8–10 mg groups. The difference in the
extent of the increase at timepoint 4 for the 67 mg resulted in a
signiﬁcant difference compared to the LSR and 8–10 mg groups.
The possibility of an analytical bias was investigated by blinded
repeat analysis of long-term stored samples from timepoints 3
and 4. The repeat analysis results conﬁrmed the original values
and implied that the analytical method was not the cause of the
observed step change. Given that the actual cause of the step
change in NNAL values remains unclear, the actual signiﬁcance of
the observed smoker group differences should be treated with cau-
tion. Further complication in the interpretation of total NNAL data
arises due to the long half-life of 10–18 days (Goniewicz et al.,
2009), which will result in contributions to the total NNAL mea-
sured from cigarettes smoked prior to the 24 h urine collection
period. Whilst the NNK smoke yields were measured for each of
the study samples, it was not feasible to obtain data on the prod-
ucts purchased and consumed by the subjects throughout the
study. These potential differences in the NNK smoke yields
between the study product batch and those purchased and con-
sumed by the subjects may have contributed to the observedtrends in total NNAL and would suggest that measurement of
NNAL in an non-conﬁned study would require a study design
which allows provision of a single batch of cigarettes of known
NNK smoke yield.
The secondary objectives of this study were to determine the
extent of any compensatory smoking behaviour as a consequence
of spontaneously switching to lower tar and nicotine yield cigar-
ettes. Whilst compensation indices can be calculated when switch-
ing to higher yield products, subjects in this study could not switch
to products with ISO tar yields greater than 10 mg due to the upper
limit of 10 mg for cigarettes sold within the European Union
(European Parliament and the Council of the European Union,
2001). Compensation indices were not calculated when subjects
switched back to LSR from a product of 7 mg ISO tar or lower,
due to the small number of observations (n = 4). The compensation
indices (CiX) shown in Table 4 reﬂect incomplete (partial) com-
pensation following a spontaneous switch from LSR to a cigarette
of 7 mg ISO tar or lower. We are aware of only two published stud-
ies of spontaneous product switching (Lynch and Benowitz, 1987;
Muhammad-Kah et al., 2011). Lynch and Benowitz reported data
from 62 smokers who switched to products with a smoke
machine-derived nicotine yield of at least 0.2 mg lower than their
previous product of 3–6 years earlier. Daily consumption
decreased on average by 6.6 cigarettes and plasma cotinine by
19%. However, cotinine data per cigarette revealed only slight
downward changes, thus demonstrating that nicotine intake per
cigarette was effectively maintained, i.e., complete compensation.
In the study by Muhammad-Kah et al. (2011), 19 smokers had
switched to products with 3 mg lower smoke machine-derived
tar yields. Due to the limited sample size and variability of urinary
biomarker levels, no ﬁrm conclusions were drawn regarding
changes in exposure. The incomplete compensation ﬁndings from
our study are in agreement with the conclusions made by
Scherer and Lee (2014) based on a review of published forced
switching studies.
A comparison of the CiX values calculated using MLE estimates
on a per cigarette and daily basis (Table 4) shows similar values
and therefore implies that changes in cigarette consumption were
minimal following spontaneous switching. This ﬁnding is consis-
tent with the Scherer (1999) conclusion that compensation is dri-
ven by changes in smoking intensity rather than consumption.
When considering the extent of compensation with increasing
duration since the initial switch (Table 5), the CiX values derived
from daily MLE values showed a downward, but non-statistically
signiﬁcant trend. These observations indicate that consumption
may decrease somewhat over time for those smokers who remain
smoking a cigarette of 7 mg ISO tar or lower. Variation in NEQ val-
ues observed in this study may explain the lack of any trend in CiX
values with increasing switching duration and the value of 1.08
(which implies an increase in intake). The negative compensation
index value observed for MLE nicotine/day implies that the reduc-
tion in intake is proportionally greater than the reduction in smoke
yield, and in this case is likely to be the result of extreme changes
in cigarette consumption for a small group size.
In general the CiX values calculated from this study lie within
the range of values observed from a number of forced-switching
studies (Scherer and Lee, 2014) and suggest that forced-switching
studies are a convenient study design to provide representative
compensatory smoking behaviour data following a switch to a
cigarette product of lower tar and nicotine yield.
5. Conclusions
In undertaking the reported study we aimed to develop a suit-
able methodology for monitoring the smoking habits of a large
smoker population in their everyday environment over an
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on the effects of spontaneous product switching on smokers’ cigar-
ette consumption and exposure to smoke constituents.
Data from this study demonstrated that repeated measures of
cigarette consumption remained stable and did not change as a
consequence of either spontaneous side- or downswitching. MLE
data for the smokers who did not switch product showed a down-
ward trend part-way through the study. Whilst analytical variation
may have caused or contributed to these trends, the results high-
light the importance of minimising analytical variation and where
possible limiting the variation of the study product over time.
Statistically signiﬁcant differences were detected between smo-
ker groups, with smokers of products of 67 mg ISO tar obtaining
lower yields compared with those who did not switch product
and those who switched to products of 8–10 mg ISO tar. However,
this trend was not observed for all timepoints. Biomarkers of expo-
sure showed the greatest variation over time and whilst differences
were detected between smoker groups, no clear trends were identi-
ﬁed over time for the different smoker groups.
Compensatory smoking behaviour as a consequence of sponta-
neous product switching was incomplete and in general agreement
with ﬁndings from forced-switching studies. Changes in smoking
intensity appear to be the driver of compensation rather than
increases in cigarette consumption.
In 2012, the US Food and Drug Administration issued draft guid-
ance on the key areas to be investigated in making a modiﬁed risk
tobacco product application, which includes the need to generate
data on how consumers use a product both in controlled and natu-
ral environments and post-market studies to provide longer-term
assessment of exposure and health outcomes (US Food and Drug
Administration, 2012). Data from this study illustrate some of the
challenges in measuring smokers’ long-term exposure to smoke
constituents and whilst non-conﬁned study designs aim to reﬂect
natural behaviours, the variability of biomarkers may limit their
value.
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